Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 14/20 | 1.00 |
| ▸ | MMP9 | P14780 | 12/20 | 1.00 |
| ▸ | MMP13 | P45452 | 10/20 | 1.00 |
| ▸ | ADAM17 | P78536 | 6/20 | 1.00 |
| ▸ | MMP2 | P08253 | 8/20 | 0.67 |
| ▸ | MMP3 | P08254 | 8/20 | 0.67 |
| ▸ | PDE4A | P27815 | 3/20 | 0.55 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.55 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.55 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | MMP7 | P09237 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6927179 | 1.00 | MMP1 (1.00) | MMP1MMP9MMP13ADAM17MMP2 | |
| SCHEMBL6929323 | 0.95 | MMP13 (1.00) | MMP1MMP9MMP13ADAM17MMP2 | |
| SCHEMBL6930723 | 0.90 | MMP13 (0.82) | MMP1MMP9MMP13ADAM17MMP2 | |
| SCHEMBL6929907 | 0.87 | MMP1 (0.77) | MMP1MMP9MMP13ADAM17MMP2 | |
| SCHEMBL7409682 | 0.86 | MMP9 (0.74) | MMP1MMP9MMP13ADAM17MMP2 | |
| SCHEMBL27535890 | 0.86 | MMP1 (0.75) | MMP1MMP9MMP13ADAM17MMP2 | |
| SCHEMBL6931676 | 0.86 | MMP1 (0.75) | MMP1MMP9MMP13ADAM17MMP2 | |
| SCHEMBL6928909 | 0.86 | MMP13 (0.75) | MMP1MMP9MMP13ADAM17MMP2 | |
| SCHEMBL27512626 | 0.86 | MMP13 (0.75) | MMP1MMP9MMP13ADAM17MMP2 | |
| SCHEMBL7346604 | 0.86 | MMP13 (0.75) | MMP1MMP9MMP13ADAM17MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2041181-B1 | SPECIFIC PROTEASE INHIBITORS AND THEIR USE IN CANCER THERAPY | HELMHOLTZ ZENTRUM MUENCHEN (DE) | 2011-05-18 | — | — | EP | claimed |
| US-20100226922-A1 | SPECIFIC PROTEASE INHIBITORS AND THEIR USE IN CANCER THERAPY | HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT (GMBH) (DE) | 2010-09-09 | — | — | US | claimed |
| EP-2041181-A1 | SPECIFIC PROTEASE INHIBITORS AND THEIR USE IN CANCER THERAPY | GSF-Forschungszentrum für Umwelt und Gesundheit GmbH (DE) | 2009-04-01 | — | — | EP | claimed |
| WO-2007141029-A1 | SPECIFIC PROTEASE INHIBITORS AND THEIR USE IN CANCER THERAPY | HELMHOLTZ ZENTRUM MÜNCHEN DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH) (DE) | 2007-12-13 | — | — | WO | claimed |
| WO-2004096206-A2 | THERAPEUTIC COMBINATION OF A COX-2 INHIBITOR AND A TACE INHIBITOR | PHARMACIA CORPORATION (US) | 2004-11-11 | — | — | WO | claimed |
| US-20040122011-A1 | Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy | PHARMACIA CORPORATION | 2004-06-24 | — | — | US | claimed |
| EP-2041181-B1 | SPECIFIC PROTEASE INHIBITORS AND THEIR USE IN CANCER THERAPY | HELMHOLTZ ZENTRUM MUENCHEN (DE) | 2011-05-18 | — | — | EP | disclosed |
| US-20100226922-A1 | SPECIFIC PROTEASE INHIBITORS AND THEIR USE IN CANCER THERAPY | HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT (GMBH) (DE) | 2010-09-09 | — | — | US | disclosed |
| US-20100168089-A1 | UTILIZATION OF TACE INHIBITORS FOR THE TREATMENT OF ACNE | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-07-01 | — | — | US | disclosed |
| US-20100168089-A1 | UTILIZATION OF TACE INHIBITORS FOR THE TREATMENT OF ACNE | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-07-01 | — | — | US | disclosed |
| EP-2041181-A1 | SPECIFIC PROTEASE INHIBITORS AND THEIR USE IN CANCER THERAPY | GSF-Forschungszentrum für Umwelt und Gesundheit GmbH (DE) | 2009-04-01 | — | — | EP | disclosed |
| WO-2007141029-A1 | SPECIFIC PROTEASE INHIBITORS AND THEIR USE IN CANCER THERAPY | HELMHOLTZ ZENTRUM MÜNCHEN DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH) (DE) | 2007-12-13 | — | — | WO | disclosed |
| EP-1865001-A1 | Specific protease inhibitors and their use in cancer therapy | GSF-FORSCHUNGSZENTRUM FÜR UMWELT UND GESUNDHEIT, GMBH (DE) | 2007-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122011-A1 | Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy | PTGES2, PTGS2, PTGIS | MMP1 67/4885MMP9 21/4885MMP13 87/4885 |
| US-20100168089-A1 | UTILIZATION OF TACE INHIBITORS FOR THE TREATMENT OF ACNE | MMP17, MMP25, TIMP3 | MMP1 16/4885MMP9 29/4885MMP13 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.